Cure8 news brief
Insurance changes and rising premiums can force people with Crohn’s disease to skip or lose access to expensive biologic medications and routine care, which patients in the article say led to loss of treatment options and a serious complication (a fistula) requiring surgery.
Adults with Crohn's disease or other chronic conditions in Florida, caregivers, clinicians treating IBD, and health policy advocates concerned with ACA marketplace changes and Medicaid expansion.
The article highlights a patient with Crohn’s disease who relies on part-time work to qualify for ACA coverage and pays substantial monthly copays for medications. She reports losing access to biologic drugs (Humira/adalimumab and Remicade/infliximab) after coverage lapses and subsequently developing a fistula that required major surgery.
The piece also explains the policy context: Florida uses the federal HealthCare.gov marketplace and did not expand Medicaid, limiting safety-net options. The article contrasts Florida with New Mexico, which used state subsidies to blunt premium increases.
This is a mainstream news article reporting patient experiences and policy analysis; clinical and causal assertions come from patient testimony and expert commentary rather than new research. Specific medication loss was reported by the patient and may reflect her individual clinical history.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn’s can sometimes cause flare-ups or complications that make working difficult or impossible; disability benefits can replace part of lost income. The article lays out the types of benefits and what the SSA looks for...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from msn.com.
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
